Tapering Methotrexate Is Feasible in Stable RA With Careful Monitoring
Long-term flare risk and remission rates did not differ between patients with well-controlled RA who tapered vs continued MTX therapy.
Among patients with well-controlled rheumatoid arthritis (RA), tapering or stopping methotrexate (MTX) doesn’t increase the risk for flares over the long term, according to study results presented at the American College of Rheumatology (ACR) Convergence 2025, held from October 24 to 29, in Chicago, IL.
Results from a prior cohort study involving patients with stable RA who were in remission while on biologics with or without MTX showed that flare risk was lowest when tapering MTX alone vs tapering biologic/targeted synthetic disease-modifying antirheumatic drugs (DMARDs).
To help confirm these findings, researchers examined the feasibility of MTX tapering among another cohort of patients with stable RA.
The retrospective cohort study was conducted at 2 tertiary care centers within the Allegheny Health Network and Penn State Health.
No direct quotes available in the text.
Author's summary: Tapering MTX is feasible in stable RA with careful monitoring.
More News
- ACT Brief: AI Partnerships, Global Trial Access, and a New Option for Menopause Symptoms | Applied Clinical Trials Online
- Why Hiring a Fishers Personal Injury Lawyer Is Key After a Car Accident, Slip, or Dog Bite | NorthPennNow
- Pirates Listed as Potential Fit for Trent Grisham, Luis Arráez and Other Top Free Agents
- Renters Rights Bill becomes law - Letting Agent Today
- Liam Hemsworth vs. Gabriella Brooks: Who Has the Higher Net Worth?
- Partnerships to innovate access to medicines - BusinessWorld Online
- The environmental impact of the 2026 World Cup
- 2 US Navy aircraft crash in South China Sea
- Why Experienced Lawyers Matter in a Personal Injury Case | NorthPennNow
- The new age of pediatric medication awareness - Express Healthcare